首页> 外文期刊>Southern Medical Journal >Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach.
【24h】

Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach.

机译:肝移植受者曲霉病:采用多步骤方法成功治疗并提高生存率。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Invasive aspergillosis is a life-threatening complication in liver transplant recipients, with a reported mortality rate of more than 90%. Treatment is difficult, and no single agent is uniformly effective in treating this patient population. METHODS: We retrospectively reviewed all fungal cultures from 200 liver transplant patients between 1996 and 1999 at a single tertiary referral center. RESULTS: A diagnosis of aspergillosis was made in 6 patients. Five patients had pulmonary involvement; 1 presented with an inguinal mass. Time from transplant to infection ranged from 1 week to 34 months. Treatment included surgical intervention and medical treatment. All patients infected with Aspergillus fumigatus were treated with a sequential protocol of lipid complex amphotericin followed by itraconazole. The major side effect of treatment was worsening renal function. One patient died of intracranial hemorrhage during treatment. CONCLUSION: Successful treatment of aspergillosis in liver transplant recipients should include early diagnosis, sequential medical treatment with lipid amphotericin B and itraconazole, and surgical intervention for invasive disease.
机译:背景:侵袭性曲霉病是威胁肝移植患者生命的并发症,据报道死亡率超过90%。治疗是困难的,并且没有单一药剂在治疗该患者人群中具有统一的效果。方法:我们回顾性研究了1996年至1999年间在单个三级转诊中心进行的200例肝移植患者的所有真菌培养。结果:6例诊断为曲霉病。 5例患者有肺部受累。 1出现腹股沟肿块。从移植到感染的时间从1周到34个月不等。治疗包括手术干预和药物治疗。所有感染了烟曲霉的患者均先后接受脂质复合物两性霉素和伊曲康唑治疗。治疗的主要副作用是肾功能恶化。一名患者在治疗期间死于颅内出血。结论:肝移植受者曲霉病的成功治疗应包括早期诊断,使用脂质两性霉素B和伊曲康唑的序贯药物治疗以及对浸润性疾病的手术干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号